Stephen E. Kimmel, MD, MSCE
Associate Professor of Medicine
Department: Medicine
Graduate Group Affiliations
Contact information
University of Pennsylvania School of Medicine
Center for Clinical Epidemiology and Biostatistics
Room 717, Blockley Hall
423 Guardian Drive
Philadelphia, PA 19104-6021
Center for Clinical Epidemiology and Biostatistics
Room 717, Blockley Hall
423 Guardian Drive
Philadelphia, PA 19104-6021
Office: 215-898-1740
Fax: 215-573-3106
Fax: 215-573-3106
Email:
stevek@mail.med.upenn.edu
stevek@mail.med.upenn.edu
Publications
Links
Search PubMed for articles
Cardiovascular Division Faculty
Clinical Pharmacogenomic Epidemiology (CPE) initiative, an Exploratory Center (P20) for Interdisciplinary Research funded by the National Institutes of Health
Center for Clinical Epidemiology and Biostatistics Faculty
Search PubMed for articles
Cardiovascular Division Faculty
Clinical Pharmacogenomic Epidemiology (CPE) initiative, an Exploratory Center (P20) for Interdisciplinary Research funded by the National Institutes of Health
Center for Clinical Epidemiology and Biostatistics Faculty
Education:
A.B. (Magna Cum Laude)
Princeton University , 1984.
M.D.
New York University School of Medicine, 1988.
M.S.C.E. (Master of Science in Clinical Epidemiology)
University of Pennsylvania, 1995.
Permanent linkA.B. (Magna Cum Laude)
Princeton University , 1984.
M.D.
New York University School of Medicine, 1988.
M.S.C.E. (Master of Science in Clinical Epidemiology)
University of Pennsylvania, 1995.
Description of CVI Expertise
Director, Cardiovascular EpidemiologyCVI Program Unit(s):
Lipid / Atherobiology/ CAD / ACS / Prevention
CVI Research Description:
Dr. Kimmel's research is in cardiovascular epidemiology with a focus on drug epidemiology, pharmacogenomics, and adherence to medications.
Dr. Kimmel's research focuses on cardiac pharmacoepidemiology, with a particular interest in the effects and proper use of drugs and devices for patients with coronary artery disease. He is currently principal investigator on a number of grants evaluating cardiac medications, including a study examining the relationship between myocardial infarction and use of nonsteroidal anti-inflammatory drugs and a study examining the effects of genetic polymorphisms and patient adherence on anticoagulation control. He is also the principal investigator of a randomized trial designed to test economic and behavioral interventions to improve adherence with antihypertensive drugs. Dr. Kimmel has extensive experience performing studies examining complications from, and the proper use of, cardiovascular devices. He also is actively studying the influence of laboratory experience on outcomes.
Selected Publications
Cruess DG, Localio AR, Platt AB, Brensinger CM, Christie JD, Gross R, Parker CS, Price M, Metlay JP, Cohen A, Newcomb CW, Strom BL, Kimmel SE: Patient Attitudinal and Behavioral Factors Associated with Warfarin Non-Adherence at Outpatient Anticoagulation Clinics. International Journal of Behavioral Medicine 2009 Jul 5 [Epub ahead of print]Hennessy S, Leonard CE, Newcomb C, Kimmel SE, Bilker WB: Antidepressants and the Risk of Emergency Department or Inpatient Admission for Sudden Cardiac Death and Ventricular Arrhythmia. (Presented at the 25th International Conference on Pharmacoepidemiology, Providence, RI). Pharmacoepidemiology and Drug Safety 18(1): S218, 2009.
Haynes K, Hennessy S, Localio AR, Cohen A, Leonard CE, Kimmel SE, Feldman HI, Strom BL, Metlay JP: Increased risk of digoxin toxicity following hospitalization. Pharmacoepidemiology and Drug Safety 18: 28-35, 2009.
Doshi JA, Zhu J, Lee BY, Kimmel SE, Volpp KG: Impact of a Prescription Copayment Increase on Lipid Lowering Medication. Circulation 119: 390-397, 2009.
Klein TE, Kimmel SE, Jonson JA: Warfarin Pharmacogenetics Reply. New England Journal of Medicine 360(23): 2475, 2009.
Ky B, Kimmel SE, Safa RN, Putt ME, Sweitzer NK, Fang JC, Sawyer DB, Cappola TP: Neuregulin-1 beta Is Associated with Cardiomyopathy Etiology, Disease Severity, and Adverse Outcomes in Chronic Heart Failure (Presented at the Heart Failure Society of America Leading Clinical Research Session, Boston, MA). Journal of Cardiac Failure 15(1): 21, 2009.
Volpp KG, Troxel A, Long J, Ibrahaim S, Appleby D, Smith J, Jaskowiak J, Wang P, Holmes JH, Frosch D, Armstrong K, Helweg-Larsen M, Doshi J, Kumanyika S, Enge K, Townsend R, Joshi N, Kimmel SE: A Randomized Controlled Trial of Copayment Reductions for Blood Pressure Medication: The Collaboration in Hypertension to Reduce Disparities (CHORD) Trial.(Presented at the General internal Medicine Meeting in Miami Beach, FL). Journal of General Internal Medicine 24(1): 9-10, 2009.
Munson JC, Kreider M, Christie JD, Kimmel SE: The Effect of Treatment Guidelines on the Initial Management of Idiopathic Pulmonary Fibrosis. (Presented at the 25th International Conference on Pharmacoepidemiology, Providence, RI) Pharmacoepidemiology and Drug Safety 18(1): S144-S145, 2009.
Ky B, Kimmel SE, Safa RN, Putt ME, Sweitzer NK, Fang JC, Sawyer DB, Cappola TP: Circulating Neuregulin-1b in Human Heart Failure. (Poster presentation at the 49th American Heart Association Cardiovascular Disease and Epidemiology Conference, Tampa, FL) 2009.
Horne BD, Lenzini P, Wadelius M, Jorgensen AL, Kimmel S, Eriksson N, Anderson DJL, Pirmohamed M, Limdi N, Burmester JK, Kurnik CM, Stein CM, Caldwell MD, Eby C, Rane A, Lindh JD, McMillin G, Pendleton R, Shin J, Kim H, Bass AR, Angchaisuksiri P, Chen J, Carlquist JF, Grice G, Dowd MB, Gage BF: Pharmacogenetic Dose Refinements after Pharmacogenetic Initiation of Warfarin Therapy. (Presented at Cold Spring Harbor Laboratories). 2009.
| Protocol | Title | Status |
|---|---|---|
| 707850 | Collaboration to Reduce Disparities in Hypertension | Recruiting |
» Top